Phoenix, Arizona
Phase 3 cancer trials in Phoenix, AZ
55 Phase 3 cancer studies are recruiting participants at sites in Phoenix as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Phoenix at a glance
- 55 studies are recruiting at a site in Phoenix.
- By phase: Phase 2/3 (4), Phase 3 (51).
- By sponsor: industry (31), university, hospital or other (21), government (3).
- By research area: Breast Cancer (14), Lung Cancer (11), Lymphoma (11), Pancreatic Cancer (8), Prostate Cancer (6), Melanoma (5).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Phoenix
Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic Cancer Center ( Site 0034)
- Registry record
- NCT06966700 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Cancer Center at Saint Joseph's · Mayo Clinic Hospital in Arizona
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Mayo Clinic Hospital in Arizona
- Registry record
- NCT06748222 · updated
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- The Dignity Health Cancer Institute
- Registry record
- NCT06790693 · updated
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- American Society of Clinical Oncology
- Study site
- Ironwood Cancer & Research Centers
- Registry record
- NCT06377852 · updated
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Ironwood Cancer & Research Centers
- Registry record
- NCT07062965 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Lung cancer studies recruiting in Phoenix
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Mayo Clinic in Arizona - Phoenix
- Registry record
- NCT07063745 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cancer Center at Saint Joseph's
- Registry record
- NCT04181060 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Banner University Medical Center Phoenix
- Registry record
- NCT06119581 · updated
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic in Arizona - Phoenix ( Site 0147)
- Registry record
- NCT06170788 · updated
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06627647 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Prostate cancer studies recruiting in Phoenix
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Cancer Center at Saint Joseph's
- Registry record
- NCT04423211 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic in Arizona - Phoenix ( Site 0044)
- Registry record
- NCT06925737 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Melanoma studies recruiting in Phoenix
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Cancer Center at Saint Joseph's
- Registry record
- NCT07068074 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Lymphoma studies recruiting in Phoenix
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic Hospital in Arizona
- Registry record
- NCT06337318 · updated
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study sites
- Mayo Clinic - Arizona · St. Joseph's Hospital and Medical Center
- Registry record
- NCT05303519 · updated
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051)
- Registry record
- NCT06136559 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Mayo Clinic Hospital in Arizona
- Registry record
- NCT06724237 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)
- Registry record
- NCT06717347 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cancer Center at Saint Joseph's · Phoenix Childrens Hospital
- Registry record
- NCT05675410 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Saint Joseph's Hospital and Medical Center
- Registry record
- NCT07215910 · updated
IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Study site
- Mayo Clinic Cancer Center
- Registry record
- NCT07104032 · updated
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Phase 3
- Ages 18 to 130
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06549595 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Phoenix
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- City of Hope
- Registry record
- NCT07562152 · updated
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic Arizona
- Registry record
- NCT07621718 · updated
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic Arizona
- Registry record
- NCT07805954 · updated
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Mayo Clinic Hospital
- Registry record
- NCT06943755 · updated
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT07252232 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Ask about studies near Phoenix
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections